Provider of customized intellectual property

[israt9623525]

About TTC At TT Consultants , we are a leading (IP), technology intelligence, business research and innovation support. Our approach blends AI and Large Language Model (LLM) tools with human expertise, delivering unmatched solutions. Our team includes trained IP experts, technology consultants, former USPTO examiners, European patent attorneys, and more. We serve Fortune 500 companies, innovators, law firms, universities, and financial institutions.

Advances in genomics and bioinformatics enable the western sahara b2b leads identification of unique tumor antigens and immune evasion mechanisms, allowing the design of highly specific and effective cell therapies. Personalized approaches can optimize treatment efficacy and minimize off-target effects. Patents supporting personalized cell therapies include U.S. Patent No. 10,167,491, which covers methods for identifying tumor-specific antigens, and U.S. Patent No. 10,548,811, which relates to personalized cancer vaccines based on neoantigens. 3.6. Safety and Control Mechanisms As cell therapies become more powerful, ensuring their safety is crucial. Researchers are developing control mechanisms, such as “suicide genes” that can be activated to eliminate engineered cells if adverse effects occur.


Additionally, improving the precision of gene editing and enhancing off-target effects are critical areas of focus to improve the overall safety profile of these therapies. Patents in this area include U.S. Patent No. 9,949,898, which covers the use of safety switches in engineered T cells, and U.S. Patent No. 10,172,914, which relates to methods for reducing off-target effects in gene editing. 4. Challenges and Circumstances While cell therapies represent significant advances in oncology, several challenges remain: 4.1. Cost and Accessibility The high cost of cell therapies limits their accessibility for many patients.